Engineered immune cells take on tough scleroderma in kids
NCT ID NCT06792344
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This early-stage trial tests whether specially engineered immune cells (CAR-T cells) can safely treat children with severe systemic sclerosis that hasn't improved with standard drugs. Twelve participants will receive a single infusion of these cells, and doctors will monitor changes in skin thickness and disease activity over six months. The goal is to see if this approach can control the disease and reduce symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 0571, China
Contact
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310053, Christmas Island
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anti-CD19 CAR-T cells
What this could lead to
If successful, this could point toward a new treatment option for children with severe systemic sclerosis that hasn't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 12 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and may not improve skin or organ function.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.